Lilly’s Search For Sepsis Biomarkers Could Provide Early Signal For Xigris Use
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Lilly is looking for sepsis biomarkers that could aid Xigris administration, exec tells FDA seminar. Data suggests Xigris, a form of activated protein C, has higher survival rates when administered early; biomarkers could be signal for use. Studies of diagnostic/prognostic role of protein C are underway
You may also be interested in...
Eisai Preps Eritoran Phase III Sepsis Trial Based On Phase II Cut In Mortality
Eisai will commence a Phase III study of eritoran (E5564) for severe sepsis by the first quarter of 2006 after a Phase II trial showed a 6.4% mortality reduction versus placebo at 28 days, the firm said Aug. 29
Lilly Xigris Efficacy Driven By Chronically Ill Patients, FDA Analyses Show
Xigris’ greater efficacy in patients with chronic health problems may account for the minimal effect on hospital discharge seen in the pivotal trial of the sepsis agent, FDA review documents maintain.
FDA Priority Review Voucher Redemption Fee Set At $4.6 Million In FY 2011
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011